Personalized medicine for non-small-cell lung cancer
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要Non-small-cell lung cancer (NSCLC) is a heterogeneous illness associated with a high mortality rate. Personalized therapy may improve treatment outcomes by identification of a specific genotypic anomaly and target-specific therapy. The most significant development in recent years was the discovery of activated EGF receptor (EGFR) mutations at exons 19 and 21. Patients with EGFR mutations respond dramatically to EGFR tyrosine kinase inhibitors such as gefitinib or erlotinib, resulting in longer progression-free survival. Multiple randomized studies, including the Iressa Pan-Asia Study and WJTOG3405, have confirmed the role of EGFR tyrosine kinase inhibitors as standard first-line therapy for patients with the EGFR mutation. In this article, we summarize the current nonpersonalized therapies and examine the available and investigational personalized therapies for patients with resectable early-stage, unresectable locally advanced, or metastatic disease.
著者Mok TS, Zhou Q, Leung L, Loong HH
期刊名稱Expert Review of Anticancer Therapy
出版年份2010
月份10
日期1
卷號10
期次10
出版社EXPERT REVIEWS
頁次1601 - 1611
國際標準期刊號1473-7140
電子國際標準期刊號1744-8328
語言英式英語
關鍵詞epidermal growth factor; erlotinib; gefitinib; individualized medicine; non-small-cell lung carcinoma; receptor; receptor protein tyrosine kinases
Web of Science 學科類別Oncology; ONCOLOGY

上次更新時間 2020-25-10 於 01:19